Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Lymphoma, B-Cell 19Lymphoma, Large B-Cell, Diffuse 18Recurrence 13Lymphoma, Non-Hodgkin 13Multiple Myeloma 12Burkitt Lymphoma 11Lymphoma, Mantle-Cell 8Lymphoma 8Leukemia, Myeloid, Acute 8Carcinoma, Hepatocellular 7Pancreatic Neoplasms 6Neoplasms 6Lymphoma, Follicular 6Leukemia, Lymphocytic, Chronic, B-Cell 6Leukemia 5Glioma 5Colorectal Neoplasms 5Stomach Neoplasms 4Leukemia, B-Cell 4Hematologic Neoplasms 4Neoplasm, Residual 3Nasopharyngeal Carcinoma 3Melanoma 3Esophageal Neoplasms 3Breast Neoplasms 3Simpson-Golabi-Behmel syndrome 2Sarcoma, Synovial 2Sarcoma, Ewing 2Rhabdomyosarcoma 2

Interventions

fludarabine phosphate 4Sensitivity and Specificity 3Cyclophosphamide 3Antigens, CD19 3ibrutinib 2Whole-Body Irradiation 2Mycophenolic Acid 2Immunotherapy, Adoptive 2Etoposide 2pevonedistat 1obinutuzumab 1nelarabine 1letermovir 1carmustine, poliferprosan 20 drug combination 1Tacrolimus 1Stem Cell Transplantation 1Specimen Handling 1Pharmacogenomic Variants 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Leukapheresis 1Lenalidomide 1Hematopoietic Stem Cell Transplantation 1Cytarabine 1Cyclosporins 1Cyclosporine 1Carmustine 1Blood Component Removal 1Biopsy 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, B-Cell × Immunotherapy, Adoptive × Clear all
NCT02819583 2016-10-25

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 1/2 Unknown
10 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

NCT02851589 2016-08-01

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 1/2 Unknown
10 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡